ArticleFuture oncology (London, England)2026

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

Derrick H W Siu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.